Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
The prognosis of EBV+ DLBCL is dismal. Previous study showed that high level of PD-L1
expression in EBV+ DLBCL. The investigators therefore design this phase II study to
investigate the safety and efficacy of sintilimab (an anti-PD-1 antibody) in combination with
R-CHOP in patients with treatment-naive EBV+ DLBCL.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University